Advanced Chart
  • Feb. 6, 2014, 4:29 AM
    • Sanofi (SNY) Q4 adjusted, or "business net profit" rose 17% to €1.81B, coming in slightly below consensus of €1.82B.
    • Net sales dropped 0.8% to €8.46B.
    • Net profit jumped to €1.06B ($1.43B) from €388M a year earlier.
    • Earnings were boosted by double-digit growth in sales of Lantus, Sanofi's blockbuster diabetes drug, revenue growth at its Genzyme rare-diseases unit, and a gradual recovery in Brazil and China. Cost cuts also helped.
    • However, falling revenue from Sanofi's vaccines and animal health units, and currency fluctuations, hurt the firm's performance.
    • The company expects business EPS to increase 4-7% at constant exchange rates in 2014, boosted by its "growth platforms" and new drug authorizations. It helps that Sanofi is beyond its patent cliff.
    • Sanofi declared a dividend of €2.80 a share for 2013 vs €2.77 in 2012. (PR)
    | Feb. 6, 2014, 4:29 AM
  • Feb. 7, 2013, 4:24 AM
    Sanofi (SNY): Q4 business net profit -24% to €1.57B vs consensus of €1.54B. Sales +0.2% to €8.53B vs €8.56B. Earnings hurt by austerity in Europe and patent expirations. Forecasts profit will be flat to -5% vs 2012, although predicts that growth will resume in H2. Declares dividend of €2.77/share, up from €2.65 last year. Reaffirms its 2015 targets and that it's "on track" to meet €2B cost-savings goal by then. Shares -3.4% in Paris. (PR)
    | Feb. 7, 2013, 4:24 AM | 1 Comment